Your browser doesn't support javascript.
The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet).
Giardino, Giuliana; Milito, Cinzia; Lougaris, Vassilios; Punziano, Alessandra; Carrabba, Maria; Cinetto, Francesco; Scarpa, Riccardo; Dellepiane, Rosa Maria; Ricci, Silvia; Rivalta, Beatrice; Conti, Francesca; Marzollo, Antonio; Firinu, Davide; Cirillo, Emilia; Lagnese, Gianluca; Cancrini, Caterina; Martire, Baldassare; Danieli, Maria Giovanna; Pession, Andrea; Vacca, Angelo; Azzari, Chiara; Fabio, Giovanna; Soresina, Annarosa; Agostini, Carlo; Spadaro, Giuseppe; Badolato, Raffaele; Cicalese, Maria Pia; Aiuti, Alessandro; Plebani, Alessandro; Quinti, Isabella; Pignata, Claudio.
  • Giardino G; Department of Translational Medical Sciences, Section of Pediatrics, Federico II University of Naples, Naples, Italy.
  • Milito C; Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • Lougaris V; Department of Clinical and Experimental Sciences, Pediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, University of Brescia, Brescia, Italy.
  • Punziano A; ASST-Spedali Civili Di Brescia, Brescia, Italy.
  • Carrabba M; Department of Translational Medical Sciences, Center for Basic and Clinical Immunology Research, University of Naples Federico II, Naples, Italy.
  • Cinetto F; Internal Medicine Department, Rare Disease Unit, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Scarpa R; Rare Disease Referral Center, Internal Medicine 1, Ca Foncello Hospital, ULSS2 Marca Trevigiana, Treviso, Italy.
  • Dellepiane RM; Department of Medicine-DIMED, University of Padova, Padua, Italy.
  • Ricci S; Rare Disease Referral Center, Internal Medicine 1, Ca Foncello Hospital, ULSS2 Marca Trevigiana, Treviso, Italy.
  • Rivalta B; Department of Medicine-DIMED, University of Padova, Padua, Italy.
  • Conti F; Department of Pediatrics, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Marzollo A; Department of Health Sciences, University of Florence, Florence, Italy.
  • Firinu D; Department of Pediatrics, Immunology Unit, Meyer Children's University Hospital, Florence, Italy.
  • Cirillo E; Unit of Immunology and Infectious Diseases, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Rome, Italy.
  • Lagnese G; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Cancrini C; Unit of Pediatrics, University of Bologna, St. Orsola University Hospital, Bologna, Italy.
  • Martire B; Department of Women's and Children's Health, Pediatric Hematology-Oncology Unit, University of Padua, Padua, Italy.
  • Danieli MG; Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.
  • Pession A; Department of Translational Medical Sciences, Section of Pediatrics, Federico II University of Naples, Naples, Italy.
  • Vacca A; Department of Translational Medical Sciences, Center for Basic and Clinical Immunology Research, University of Naples Federico II, Naples, Italy.
  • Azzari C; Unit of Immunology and Infectious Diseases, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Rome, Italy.
  • Fabio G; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Soresina A; Unit of Pediatrics and Neonatology, "Monsignor A.R. Dimiccoli" Hospital, Barletta, Italy.
  • Agostini C; Clinica Medica, Dipartimento Di Scienze Cliniche E Molecolari, Università Politecnica Delle Marche E Azienda Ospedali Riuniti, Ancona, Italy.
  • Spadaro G; Unit of Pediatrics, University of Bologna, St. Orsola University Hospital, Bologna, Italy.
  • Badolato R; Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy.
  • Cicalese MP; Department of Health Sciences, University of Florence, Florence, Italy.
  • Aiuti A; Department of Pediatrics, Immunology Unit, Meyer Children's University Hospital, Florence, Italy.
  • Plebani A; Internal Medicine Department, Rare Disease Unit, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Quinti I; Department of Clinical and Experimental Sciences, Pediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, University of Brescia, Brescia, Italy.
  • Pignata C; ASST-Spedali Civili Di Brescia, Brescia, Italy.
J Clin Immunol ; 42(5): 935-946, 2022 07.
Article in English | MEDLINE | ID: covidwho-1802997
ABSTRACT
COVID-19 manifestations range from asymptomatic to life-threatening infections. The outcome in different inborn errors of immunity (IEI) is still a matter of debate. In this retrospective study, we describe the experience of the of the Italian Primary Immunodeficiencies Network (IPINet). Sixteen reference centers for adult or pediatric IEI were involved. One hundred fourteen patients were enrolled including 35 pediatric and 79 adult patients. Median age was 32 years, and male-to-female ratio was 1.51. The most common IEI were 22q11.2 deletion syndrome in children (26%) and common variable immunodeficiency (CVID) in adults (65%). Ninety-one patients did not require hospital admission, and among these, 33 were asymptomatic. Hospitalization rate was 20.17%. Older age (p 0.004) and chronic lung disease (p 0.0008) represented risk factors for hospitalization. Hospitalized patients mainly included adults suffering from humoral immunodeficiencies requiring immunoglobulin replacement therapy and as expected had lower B cell counts compared to non-hospitalized patients. Infection fatality rate in the whole cohort was 3.5%. Seroconversion was observed is 86.6% of the patients evaluated and in 83.3% of CVID patients. 16.85% of the patients reported long-lasting COVID symptoms. All but one patient with prolonged symptoms were under IgRT. The fatality rate observed in IEI was slightly similar to the general population. The age of the patients who did not survive was lower compared to the general population, and the age stratified mortality in the 50-60 age range considerable exceeded the mortality from 50 to 60 age group of the Italian population (14.3 vs 0.6%; p < 0.0001). We hypothesize that this is due to the fact that comorbidities in IEI patients are very common and usually appear early in life.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Common Variable Immunodeficiency / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Child / Female / Humans / Male Language: English Journal: J Clin Immunol Year: 2022 Document Type: Article Affiliation country: S10875-022-01264-y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Common Variable Immunodeficiency / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Child / Female / Humans / Male Language: English Journal: J Clin Immunol Year: 2022 Document Type: Article Affiliation country: S10875-022-01264-y